Amicus Therapeutics Inc - Asset Resilience Ratio
Amicus Therapeutics Inc (FOLD) has an Asset Resilience Ratio of 8.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amicus Therapeutics Inc (FOLD) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Amicus Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Amicus Therapeutics Inc (FOLD) total assets.
Liquid Assets Composition Over Time
This chart breaks down Amicus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore FOLD long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $79.53 Million | 8.37% |
| Total Liquid Assets | $79.53 Million | 8.37% |
Asset Resilience Insights
- Limited Liquidity: Amicus Therapeutics Inc maintains only 8.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amicus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Amicus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Amicus Therapeutics Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Amicus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.37% | $79.53 Million | $949.87 Million | +3.76pp |
| 2024-12-31 | 4.61% | $36.19 Million | $785.03 Million | -0.43pp |
| 2023-12-31 | 5.04% | $39.21 Million | $777.88 Million | -14.95pp |
| 2022-12-31 | 19.99% | $144.78 Million | $724.17 Million | -6.22pp |
| 2021-12-31 | 26.22% | $237.30 Million | $905.14 Million | -9.88pp |
| 2020-12-31 | 36.10% | $320.03 Million | $886.52 Million | -0.35pp |
| 2019-12-31 | 36.45% | $309.90 Million | $850.21 Million | -17.27pp |
| 2018-12-31 | 53.73% | $424.40 Million | $789.95 Million | +4.36pp |
| 2017-12-31 | 49.36% | $309.50 Million | $627.02 Million | +35.54pp |
| 2016-12-31 | 13.82% | $143.32 Million | $1.04 Billion | -2.09pp |
| 2015-12-31 | 15.91% | $144.55 Million | $908.38 Million | -44.86pp |
| 2014-12-31 | 60.77% | $127.60 Million | $209.97 Million | +30.70pp |
| 2013-12-31 | 30.07% | $38.36 Million | $127.56 Million | -29.11pp |
| 2012-12-31 | 59.18% | $65.15 Million | $110.09 Million | +16.15pp |
| 2011-12-31 | 43.03% | $30.03 Million | $69.80 Million | -26.16pp |
| 2010-12-31 | 69.19% | $77.87 Million | $112.55 Million | +0.21pp |
| 2009-12-31 | 68.98% | $58.88 Million | $85.37 Million | -3.28pp |
| 2008-12-31 | 72.26% | $93.05 Million | $128.77 Million | +2.04pp |
| 2007-12-31 | 70.22% | $117.34 Million | $167.10 Million | -1.15pp |
| 2006-12-31 | 71.38% | $42.57 Million | $59.65 Million | +8.70pp |
| 2005-12-31 | 62.68% | $17.97 Million | $28.67 Million | -17.73pp |
| 2004-12-31 | 80.41% | $4.08 Million | $5.07 Million | -- |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more